2-(p-methoxystyryl)-α,α,α-trifluorotoluene | 917471-59-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-(p-methoxystyryl)-α,α,α-trifluorotoluene
• 英文别名: (E)-1-(4-methoxystyryl)-2-(trifluoromethyl)benzene；(E)-2-trifluoromethyl-4'-methoxystilbene；(E)-2-(Trifluoromethyl)-4'-methoxystilbene；1-methoxy-4-[(E)-2-[2-(trifluoromethyl)phenyl]ethenyl]benzene
• CAS: 917471-59-1
• 化学式: C₁₆H₁₃F₃O
• 分子量: 278.274
• InChiKey: YNYFLRUMPHKZQP-RMKNXTFCSA-N

物化性质

• 沸点：
  341.8±37.0 °C(Predicted)
• 密度：
  1.209±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(p-methoxystyryl)-α,α,α-trifluorotoluene 在 lithium aluminium tetrahydride 、 niobium pentachloride 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以66%的产率得到2-(4-甲氧基苯基)-1H-茚
  参考文献：
  名称：

  Low-valent Niobium-mediated Synthesis of Indenes: Intramolecular Coupling Reaction of CF₃Group with Alkene C–H Bond

  摘要：

  CF3取代的o-烯烃-α,α,α-三氟甲苯在NbCl5/LiAlH4体系下与烯烃C–H键发生了分子内偶联反应。获得了产率良好的取代茚类化合物。

  DOI：

  10.1246/cl.2007.24
• 作为产物：
  描述：

  2-(三氟甲基)苯乙烯 在 bis(triphenylphosphine)nickel(II) chloride 、 potassium carbonate 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 19.08h， 生成 2-(p-methoxystyryl)-α,α,α-trifluorotoluene
  参考文献：
  名称：

  中断的Pummerer /镍催化交叉偶联序列

  摘要：

  已经开发了一种中断的Pummerer /镍催化的交叉偶联策略，并将其用于苯乙烯的精制。操作简单的方法可以作为一个锅法进行，涉及直接形成稳定的烯基sulf盐中间体，利用市售的亚砜，催化剂和配体，在环境温度下操作，可容纳sp‐，sp 2‐，和sp 3杂交的有机锌偶联伙伴，并通过两个步骤以高收率提供官能化的苯乙烯产品。中断的Pummerer /环化方法也已用于获得碳和杂环烯基sulf盐进行交叉偶联。

  DOI：

  10.1002/anie.201805396

文献信息

• Substituted CIS- and trans-stilbenes as therapeutic agents
  申请人：Vander Jagt David L.

  公开号：US20070249647A1

  公开（公告）日：2007-10-25

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

  本发明涉及治疗患有癌症或癌前病变、炎症性疾病或病情以及中风或其他缺血性疾病或病情的方法，该方法包括向需要的受试者或患者施用含有一定治疗有效量的取代的顺式或反式-芪的组合物。
• E-selective isomerization of stilbenes and stilbenoids through reversible hydroboration
  作者：Erin E. Gray、Lake E. Rabenold、Brian C. Goess

  DOI：10.1016/j.tetlet.2011.09.046

  日期：2011.11

  Hydroboration of a mixture of E and Z stilbenes and stilbenoids is followed by an elimination reaction to yield the E isomer with high stereoselectivity. The reaction tolerates aromatic substituents with varying stereoelectronic properties, occurs in one pot, and requires only commercially available reagents. An illustration of the isomerization reaction in a synthesis of resveratrol, a biologically

  E和Z的Stilbenes和Stilbenoids的混合物进行氢硼化后，进行消除反应，得到具有高立体选择性的E异构体。该反应容许具有不同立体电子性质的芳族取代基，发生在一个罐中，并且仅需要可商购的试剂。给出了白藜芦醇（一种生物活性抗氧化剂）的合成中的异构化反应的说明。
• Substituted <i>trans</i>-Stilbenes, Including Analogues of the Natural Product Resveratrol, Inhibit the Human Tumor Necrosis Factor Alpha-Induced Activation of Transcription Factor Nuclear Factor KappaB
  作者：Justin J. Heynekamp、Waylon M. Weber、Lucy A. Hunsaker、Amanda M. Gonzales、Robert A. Orlando、Lorraine M. Deck、David L. Vander Jagt

  DOI：10.1021/jm060630x

  日期：2006.11.30

  The transcription factor nuclear factor kappaB (NF-kappa B), which regulates expression of numerous antiinflammatory genes as well as genes that promote development of the prosurvival, antiapoptotic state is up-regulated in many cancer cells. The natural product resveratrol, a polyphenolic trans-stilbene, has numerous biological activities and is a known inhibitor of activation of NF-kappa B, which may account for some of its biological activities. Resveratrol exhibits activity against a wide variety of cancer cells and has demonstrated activity as a cancer chemopreventive against all stages, i.e., initiation, promotion, and progression. The biological activities of resveratrol are often ascribed to its antioxidant activity. Both antioxidant activity and biological activities of analogues of resveratrol depend upon the number and location of the hydroxy groups. In the present study, phenolic analogues of resveratrol and a series of substituted trans-stilbenes without hydroxy groups were compared with resveratrol for their abilities to inhibit the human tumor necrosis factor alpha-induced (TNF-alpha) activation of NF-kappa B, using the Panomics NF-kappa B stable reporter cell line 293/NF-kappa B-luc. A series of 75 compounds was screened to identify substituted trans-stilbenes that were more active than resveratrol. Dose-response studies of the most active compounds were carried out to obtain IC50 values. Numerous compounds were identified that were more active than resveratrol, including compounds that were devoid of hydroxy groups and were 100-fold more potent than resveratrol. The substituted trans-stilbenes that were potent inhibitors of the activation of NF-kappa B generally did not exhibit antioxidant activity. The results from screening were confirmed using BV-2 microglial cells where resveratrol and analogues were shown to inhibit LPS-induced COX-2 expression.
• SUBSTITUTED CIS- AND TRANS-STILBENES AS THERAPEUTIC AGENTS
  申请人：STC. UNM

  公开号：US20130178536A1

  公开（公告）日：2013-07-11

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene. A method of treating or reducing the likelihood of Alzheimer's disease in a patient is an additional embodiment of the present invention.
• THERAPEUTIC AGENTS FOR SKIN DISEASES AND CONDITIONS
  申请人：STC. UNM

  公开号：US20160287531A1

  公开（公告）日：2016-10-06

  The present invention relates to method(s) of treating a subject afflicted with a skin disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene or a stilbene hybrid. A method of treating or reducing the likelihood of a skin disease or condition in a patient is an additional embodiment of the present invention. Preferred pharmaceutical compositions of the invention include nanoemulsions comprising a therapeutically effective amount of a substituted cis or trans-stilbene or stilbene hybrid and at least one antibiotic.